MARC details
000 -LEADER |
fixed length control field |
03348nam a22005657a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
200210s20192019 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
1947-6108 |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.14797/mdcj-15-4-250 [doi] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
PMC6977568 [pmc] |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
31988685 |
245 ## - TITLE STATEMENT |
Title |
Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies. [Review] |
251 ## - Source |
Source |
Methodist DeBakey cardiovascular journal. 15(4):250-257, 2019 Oct-Dec. |
252 ## - Abbreviated Source |
Abbreviated source |
Methodist Debakey Cardiovasc J. 15(4):250-257, 2019 Oct-Dec. |
252 ## - Abbreviated Source |
Former abbreviated source |
Methodist Debakey Cardiovasc J. 15(4):250-257, 2019 Oct-Dec. |
253 ## - Journal Name |
Journal name |
Methodist DeBakey cardiovascular journal |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2019 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2020 |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
Publication status |
ppublish |
266 ## - Date added to catalog |
Date added to catalog |
2020-02-10 |
268 ## - Previous citation |
-- |
Methodist DeBakey cardiovascular journal. 15(4):250-257, 2019 Oct-Dec. |
520 ## - SUMMARY, ETC. |
Abstract |
Tumor-targeted therapies such as trastuzumab have led to significant improvements in survival of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, these therapies have also been associated with significant left ventricular dysfunction. The incidence of trastuzumab-induced heart failure has decreased significantly since the initial reports, in large part due to improved screening, closer monitoring for early changes in left ventricular function, and a significant decrease in the concurrent administration of anthracyclines. The mechanism of trastuzumab cardiotoxicity is still not well understood, but current knowledge suggests that ErbB2 inhibition in cardiac myocytes plays a key role. In addition to trastuzumab and other HER2-targeted agents, vascular endothelial growth factor inhibitors, proteasome inhibitors, and immune checkpoint inhibitors are all additional classes of drugs used with great success in the treatment of solid tumors and hematologic malignancies. Yet these, too, have been associated with cardiac toxicity that ranges from a mild asymptomatic decrease in ejection fraction to fulminant myocarditis. In this review, we summarize the cardiotoxic effects of tumor-targeted and immunotherapies with a focus on HER2 antagonists. Copyright (c) 2019 Houston Methodist Hospital Houston, Texas. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Antineoplastic Agents, Immunological/ae [Adverse Effects] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Heart Failure/ci [Chemically Induced] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Immunotherapy/ae [Adverse Effects] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Molecular Targeted Therapy/ae [Adverse Effects] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Animals |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cardiotoxicity |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Heart Failure/ep [Epidemiology] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Heart Failure/pp [Physiopathology] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Heart Failure/th [Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Humans |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Prognosis |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Risk Assessment |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Risk Factors |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Heart & Vascular Institutena |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Union Memorial Hospital |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Washington Hospital Center |
656 ## - INDEX TERM--OCCUPATION |
Department |
Cardio-Oncology |
656 ## - INDEX TERM--OCCUPATION |
Department |
Medicine/Internal Medicine |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Review |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Agunbiade, Tolulope A |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Barac, Ana |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Zaghlol, Raja |
790 ## - Authors |
All authors |
Agunbiade TA, Barac A, Zaghlol RY |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.14797/mdcj-15-4-250">https://dx.doi.org/10.14797/mdcj-15-4-250</a> |
Public note |
https://dx.doi.org/10.14797/mdcj-15-4-250 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |